Skip to main content

Refine your results

Filters

Displaying 3981 - 4000 of 4875

Cases and Proceedings

General Dynamics Corporation., In the Matter of

The consent order settled charges that General Dynamics’ proposed $275 million acquisition of SNC Technologies, Inc. and SNC Technologies, Corp. would likely undermine competition by bringing together two of only three competitors providing the U.S. military with melt-pour load, assemble, and pack (LAP) services used during the manufacture of ammunition for mortars and artillery. Absent relief, the proposed acquisition would likely force the U.S. military to pay higher prices for these munitions. General Dynamics is required to sell its interest in American Ordnance to an FTC-approved buyer within four months of acquiring SNC.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
0610150
Docket Number
C-4181
Cases and Proceedings

Duncan, Dan L., EPCO, Inc., Texas Eastern Products Pipeline Company, LLC, and TEPPCO Partners, LP, In the Matter of

Enterprise Products Partners L.P. settled charges that its $1.1 billion acquisition of TEPPCO Partners’ NGLs salt dome storage businesses would likely result in higher prices and service degradations by reducing the number of commercial salt dome NGL storage providers in Mont Belvieu, Texas, from four to three. The FTC’s order required TEPPCO to divest its interests in the world’s largest NGL storage facility in Mont Belvieu, Texas, to an FTC-approved buyer.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
0510108
Feb13
Event

Broadband Connectivity Competition Policy

-
The FTC hosted a public workshop on that brought together experts from business, government, and the technology sector, consumer advocates, and academics to explore competition and consumer protection...
Cases and Proceedings

TC Group, LLC., Riverstone Holdings LLC, Carlyle/Riverstone Global Energy and Power Fund II, LP, and Carlyle/Riverstone Global Energy and Power Fund III, LP, In the Matter of

The order settles charges that the proposed $22 billion deal whereby energy transportation, storage, and distribution firm Kinder Morgan, Inc. (KMI) would be taken private by KMI management and a group of investment firms, including private equity funds managed and controlled by The Carlyle Group (Carlyle) and Riverstone Holdings LLC (Riverstone) would threaten competition between KMI and Magellan in eleven metropolitan areas in the Southeast, likely resulting in higher prices for gasoline and other light petroleum products. The order requires that Carlyle’s and Riverstone’s interest in Magellan become a passive investment, by requiring them to: (1) removing all of their representatives from the Magellan Board of Managers and its boards of directors, (2) ceding control of Magellan to its other principal investor, Madison Dearborn Partners, and (3) not influencing or attempting to influence the management or operation of Magellan.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
0610197
Docket Number
C-4183
Cases and Proceedings

Johnson & Johnson and Pfizer Inc., In the Matter of

The consent order settles charges that Johnson & Johnson’s (J&J) proposed $16.6 billion acquisition of Pfizer Inc.’s (Pfizer) Consumer Healthcare business would likely reduce competition in the U.S. markets for over-the-counter (OTC) H-2 blockers used to prevent and relieve heartburn, OTC hydrocortisone anti-itch products, OTC night-time sleep aids, and OTC diaper rash treatments. In settling the Commission’s charges, the companies have agreed to sell Pfizer’s Zantac H-2 blocker business to Boehringer Ingelheim Pharmaceuticals Inc. (Boehringer), and Pfizer’s Cortizone hydrocortisone anti-itch business, Pfizer’s Unisom night-time sleep aid business, and J&J’s Balmex diaper rash treatment business to Chattem, Inc.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
0610220
Docket Number
C-4180
Press Release

FTC Challenges Hospira/Mayne Pharma Deal

Date
To Protect Competition, Companies Must Sell Assets for Five Generic Injectable Drugs The Federal Trade Commission today announced its challenge to Hospira Inc.’s (Hospira) proposed $2 billion...
Cases and Proceedings

Advocate Health Partners, et al., In the Matter of

The final consent order settles charges that the conduct of several organizations representing more than 2,900 independent Chicago-area physicians for agreeing to fix prices and for refusing to deal with certain health plans except on collectively determined terms. The order will prohibit the respondents from engaging in such anticompetitive conduct in the future.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
031 0021
Cases and Proceedings

Watson Pharmaceuticals, Inc. and Andrx Corporation., In the Matter of

A consent order settled charges that Watson Pharmaceuticals, Inc.’s proposed $1.9 billion acquisition of Andrx Corporation, would have likely led to competitive problems in the markets for 13 generic drug products. Watson was required to end its marketing agreements with Interpham Holdings, divest Andrx’s right to develop, make, and market generic extended release tablets that correct the effects of type 2 diabetes, and divest Andrx’s rights and assets related to the developing and marketing of 11 generic oral contraceptives.

There is a related federal proceeding and two related administrative proceedings:

Type of Action
Administrative
Last Updated
FTC Matter/File Number
0610139
Docket Number
C-4172

Displaying 3981 - 4000 of 4875

Return to top